RAPT Therapeutics (NASDAQ:RAPT) Upgraded by HC Wainwright to Buy Rating

HC Wainwright upgraded shares of RAPT Therapeutics (NASDAQ:RAPT) from a neutral rating to a buy rating in a report released on Thursday, MarketBeat reports. The brokerage currently has $10.00 price target on the stock.

Several other research analysts have also issued reports on the company. Piper Sandler lowered RAPT Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $8.00 to $2.00 in a research report on Monday, November 11th. Wells Fargo & Company decreased their target price on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a research report on Tuesday, November 12th. JPMorgan Chase & Co. downgraded shares of RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Monday, November 11th. UBS Group dropped their price objective on RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating on the stock in a research note on Monday, September 9th. Finally, Stifel Nicolaus reissued a “hold” rating and issued a $2.00 target price (down from $7.00) on shares of RAPT Therapeutics in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, RAPT Therapeutics has an average rating of “Hold” and an average price target of $9.56.

RAPT Therapeutics Stock Up 4.6 %

RAPT Therapeutics stock opened at $1.81 on Thursday. The stock has a market cap of $63.27 million, a price-to-earnings ratio of -0.65 and a beta of 0.07. RAPT Therapeutics has a 12 month low of $0.79 and a 12 month high of $27.35. The business has a 50 day moving average price of $1.50 and a two-hundred day moving average price of $2.19.

RAPT Therapeutics (NASDAQ:RAPT) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.09. On average, analysts expect that RAPT Therapeutics will post -2.86 earnings per share for the current fiscal year.

Hedge Funds Weigh In On RAPT Therapeutics

Several large investors have recently modified their holdings of the business. JPMorgan Chase & Co. boosted its position in RAPT Therapeutics by 298.2% during the third quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock valued at $34,000 after acquiring an additional 25,130 shares during the last quarter. Readystate Asset Management LP acquired a new position in RAPT Therapeutics in the third quarter valued at approximately $36,000. Barclays PLC boosted its holdings in shares of RAPT Therapeutics by 277.2% during the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock worth $79,000 after buying an additional 29,195 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of RAPT Therapeutics during the 2nd quarter worth approximately $108,000. Finally, Exchange Traded Concepts LLC increased its stake in shares of RAPT Therapeutics by 244.7% in the 3rd quarter. Exchange Traded Concepts LLC now owns 89,076 shares of the company’s stock valued at $179,000 after acquiring an additional 63,235 shares in the last quarter. Institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.